Abexinostat Tosylate + Fulvestrant + Palbociclib

Phase 1Withdrawn

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Anatomic Stage III Breast Cancer AJCC v8

Conditions

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Endometrioid Adenocarcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Breast Carcinoma, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8

Trial Timeline

Mar 31, 2021 → Jun 30, 2025

NCT ID

NCT04498520

About Abexinostat Tosylate + Fulvestrant + Palbociclib

Abexinostat Tosylate + Fulvestrant + Palbociclib is a phase 1 stage product being developed by Pfizer for Anatomic Stage III Breast Cancer AJCC v8. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04498520. Target conditions include Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04498520	Phase 1	Withdrawn	Mar 31, 2021	Jun 30, 2025	Anatomic Stage III Breast Cancer AJCC v8

Competing Products

13 competing products in Anatomic Stage III Breast Cancer AJCC v8

See all competitors

Product	Company	Stage	Hype Score
Abemaciclib + Niraparib Tosylate Monohydrate	Eli Lilly	Phase 1	33
Capivasertib + Ceralasertib + Durvalumab + Olaparib + Selumetinib	AstraZeneca	Phase 2	52
Pembrolizumab + Tamoxifen + Vorinostat	Merck	Phase 2	52
Carboplatin + Docetaxel + Fulvestrant + Pertuzumab + Ribociclib + Trastuzumab + Tucatinib	Novartis	Phase 1/2	41
Lutetium Lu 177 Dotatate	Novartis	Phase 2	52
Anastrozole + Exemestane + Fulvestrant + Letrozole + Paclitaxel + Talimogene Laherparepvec + Tamoxifen + Nab paclitaxel + Gemcitabine + Carboplatin	Amgen	Phase 1	32
Sacituzumab Govitecan	Gilead Sciences	Phase 2	51
Anastrozole + Exemestane + Fulvestrant + Letrozole + Palbociclib + Tamoxifen	Pfizer	Phase 2	51
Aromatase Inhibition Therapy	Bristol Myers Squibb	Pre-clinical	22
Pelareorep + Retifanlimab	Incyte	Phase 2	49
Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody	Imugene	Phase 1	25
Neratinib	Puma Biotechnology	Phase 2	44
Ivermectin + Balstilmab + Pembrolizumab	Agenus	Phase 1/2	33

Other Products from Pfizer